Posted On: 09/06/2014 10:32:45 AM
Post# of 30035
Selection of MANF manufacturer, tox data.
There was a lot of talk from Urano a while back about prioritizing the treatment of blindness associated with Wolframs. What happened with that? It aligns very well with RP. Also notice the company description at the beginning of PR's now, it says 'opthamological disorders' or something to that effect. Also, what happened with ototoxicity? Lastly, what's going on with TBI/CTE for Lympro. These are all not likely in 2014 but could be surprises and have not been discussed much recently.
One more thing. GC did state in his recent blog, potential MANF business development.
There was a lot of talk from Urano a while back about prioritizing the treatment of blindness associated with Wolframs. What happened with that? It aligns very well with RP. Also notice the company description at the beginning of PR's now, it says 'opthamological disorders' or something to that effect. Also, what happened with ototoxicity? Lastly, what's going on with TBI/CTE for Lympro. These are all not likely in 2014 but could be surprises and have not been discussed much recently.
One more thing. GC did state in his recent blog, potential MANF business development.
(0)
(0)Scroll down for more posts ▼
